Astera Labs, Inc. (ALAB) Key Metrics
ALAB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $49.59B
- Enterprise value
- $61.35B
- P/E (TTM)
- 140.8
- Forward P/E
- 55.6
- PEG ratio
- —
- Price / sales
- 41.3
- Price / book
- 36.2
- EV / EBITDA
- 215.0
- Dividend yield
- —
- Beta
- 3.69
ALAB key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsALAB valuation Price multiples at each fiscal year-end price.
ALAB returns How much profit the business earns on the capital it uses.
ALAB per-share figures Results divided by the shares outstanding at year-end.
ALAB financial health Debt, liquidity and how easily interest is covered.
ALAB efficiency & capital use Working capital cycle and where the cash goes.
ALAB valuation history
ALAB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ALAB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ALAB cash returned to shareholders
ALAB price vs earnings per share
ALAB key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $29.87B | $17.39B | — | — |
| Enterprise value | $28.72B | $16.47B | — | — |
| P/E ratio | 136.3 | — | — | — |
| Price / sales | 35.0 | 43.9 | — | — |
| Price / book | 21.9 | 18.0 | — | — |
| Price / free cash flow | 106.0 | 169.7 | — | — |
| Price / operating cash flow | 93.5 | 127.2 | — | — |
| EV / sales | 33.7 | 41.6 | — | — |
| EV / EBITDA | 127.6 | — | — | — |
| EV / free cash flow | 101.9 | 160.8 | — | — |
| Earnings yield | 0.7% | −0.5% | — | — |
| Free cash flow yield | 0.9% | 0.6% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $166.36 | $132.45 | — | — |
| Per share | ||||
| Revenue per share | $4.75 | $3.02 | $0.76 | $0.61 |
| Earnings per share | $1.22 | −$0.64 | −$0.17 | −$0.45 |
| Operating cash flow per share | $1.78 | $1.04 | −$0.08 | −$0.28 |
| Free cash flow per share | $1.57 | $0.78 | −$0.10 | −$0.30 |
| Cash per share | $6.62 | $6.97 | $0.98 | $1.25 |
| Book value per share | $7.59 | $7.35 | $1.03 | −$0.65 |
| Tangible book value per share | $7.59 | $7.35 | $1.03 | −$0.65 |
| Capex per share | $0.21 | $0.26 | $0.02 | $0.03 |
| Debt per share | $0.20 | $0.01 | $0.02 | $0.01 |
| Shares outstanding | 179.6M | 131.3M | 152.5M | 130.5M |
| Change in shares outstanding | +36.8% | −13.9% | +16.9% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | 18.8% | −14.9% | −72.8% | — |
| Return on invested capital (ROIC) | 132.5% | −291.9% | — | — |
| Return on assets (ROA) | 16.9% | −13.3% | −12.9% | −27.6% |
| Return on tangible assets | 14.3% | −7.9% | −13.4% | −27.6% |
| Free cash flow margin | 33.1% | 25.8% | −13.4% | −49.8% |
| Income quality (OCF / net income) | 1.46 | — | — | — |
| Financial health | ||||
| Total debt | $35.1M | $1.3M | $2.9M | $1.6M |
| Cash & short-term investments | $1.19B | $914.3M | $149.3M | $163.1M |
| Net debt | −$1.15B | −$913.0M | −$146.4M | −$161.5M |
| Debt / equity | 0.03 | 0.00 | 0.02 | — |
| Debt / assets | 0.02 | 0.00 | 0.01 | 0.01 |
| Net debt / EBITDA | −5.13 | — | — | — |
| Current ratio | 10.24 | 11.71 | 5.30 | 5.14 |
| Quick ratio | 9.79 | 11.21 | 4.61 | 4.42 |
| Working capital | $1.23B | $926.4M | $150.7M | $165.9M |
| Invested capital | $210.0M | $51.8M | $11.0M | −$246.8M |
| Tangible asset value | $1.36B | $964.8M | $157.4M | −$85.3M |
| Net current asset value | $1.19B | $923.3M | $146.9M | −$91.0M |
| Graham number | $14.44 | — | — | — |
| Graham net-net per share | $6.20 | $6.67 | $0.84 | −$0.85 |
| Capital allocation | ||||
| Share buybacks (net) | $0 | $1.1M | $210,000 | $313,000 |
| Dividends + buybacks / free cash flow | 0.0% | 1.0% | — | — |
| Capex / revenue | 4.4% | 8.6% | 2.4% | 4.8% |
| Capex / operating cash flow | 11.8% | 25.1% | — | — |
| Capex / depreciation | 5.50 | 10.86 | 1.55 | 4.80 |
| Stock-based compensation / revenue | 18.8% | 59.2% | 9.2% | 37.9% |
| R&D / revenue | 35.7% | 50.7% | 63.4% | 92.3% |
| SG&A / revenue | 19.7% | 55.0% | 31.0% | 56.5% |
| Efficiency | ||||
| Days sales outstanding | 26.1 | 21.7 | 30.0 | 49.0 |
| Days of inventory on hand | 90.0 | 131.3 | 268.8 | 497.3 |
| Days payables outstanding | 61.0 | 64.8 | 84.4 | 177.3 |
| Cash conversion cycle (days) | 55.1 | 88.1 | 214.4 | 369.0 |
| Receivables turnover | 13.97 | 16.81 | 12.15 | 7.45 |
| Payables turnover | 5.98 | 5.63 | 4.33 | 2.06 |
| Inventory turnover | 4.06 | 2.78 | 1.36 | 0.73 |
| Asset turnover | 0.66 | 0.63 | 0.57 | 0.38 |
| Average receivables | $61.0M | $23.6M | $9.5M | $10.7M |
| Average payables | $34.6M | $16.6M | $8.3M | $10.3M |
| Average inventory | $51.1M | $33.7M | $26.5M | $28.9M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ALAB's annual financial statements (latest annual report filed February 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ALAB valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Astera Labs traded at 136.3 times earnings. Based on the latest twelve months, the trailing P/E is 140.8 and the forward P/E is 55.6. Astera Labs earned a return on equity of 18.8% and a return on invested capital of 132.5% in fiscal 2025. It ended the year with $35.1 million of debt and $1.2 billion in cash and short-term investments, a net cash position of $1.2 billion.
See the ALAB income statement, the ALAB chart for price history, or the ALAB stock overview for the latest quote and news.
ALAB key metrics FAQ
What is Astera Labs's P/E ratio?
Astera Labs's trailing P/E ratio is 140.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 55.6. At the end of fiscal 2025 it was 136.3.
What is Astera Labs's EV/EBITDA?
Astera Labs's enterprise value was 127.6 times EBITDA at the end of fiscal 2025 (enterprise value $28.7 billion, EBITDA $225.0 million); the current EV/EBITDA is 215.0.
What is Astera Labs's return on equity?
Astera Labs's return on equity (ROE) was 18.8% in fiscal 2025: net income of $219.1 million on average shareholders' equity of $1.2 billion.
What is Astera Labs's ROIC?
Astera Labs's return on invested capital was 132.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Astera Labs have?
Astera Labs had total debt of $35.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Astera Labs's free cash flow yield?
Astera Labs generated $281.8 million of free cash flow in fiscal 2025, a free cash flow yield of 0.9% on its market value at year-end ($29.9 billion).
What is Astera Labs's current ratio?
Astera Labs's current ratio was 10.24 at the end of fiscal 2025: current assets were 10.24 times current liabilities.